These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 11810867)
1. How do abacavir and efavirenz differ in pharmacokinetics and toxicity? Edmunds-Ogbuokiri J Fac Notes (New Orleans La); 1999; 11(3):1-4. PubMed ID: 11810867 [No Abstract] [Full Text] [Related]
2. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection. Wolbach J; Capoccia K Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297 [No Abstract] [Full Text] [Related]
3. Efavirenz. Porche DJ J Assoc Nurses AIDS Care; 2000; 11(3):95-8. PubMed ID: 10826308 [No Abstract] [Full Text] [Related]
4. Options when HIV treatments fail. Treat Rev; 1998; (No 28):7-9. PubMed ID: 11365426 [TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140 [TBL] [Abstract][Full Text] [Related]
6. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Falloon J; Piscitelli S; Vogel S; Sadler B; Mitsuya H; Kavlick MF; Yoshimura K; Rogers M; LaFon S; Manion DJ; Lane HC; Masur H Clin Infect Dis; 2000 Feb; 30(2):313-8. PubMed ID: 10671334 [TBL] [Abstract][Full Text] [Related]
7. New expanded access drugs for use in combination therapy. Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823 [TBL] [Abstract][Full Text] [Related]
8. Hypersensitivity syndrome associated with efavirenz therapy. Bossi P; Colin D; Bricaire F; Caumes E Clin Infect Dis; 2000 Jan; 30(1):227-8. PubMed ID: 10619772 [No Abstract] [Full Text] [Related]
9. Selected highlights from the 5th Conference on Retroviruses and Opportunistic Infections. Bartnof HS BETA; 1998 Apr; ():49-56. PubMed ID: 11365269 [TBL] [Abstract][Full Text] [Related]
10. Human genetic variability and HIV treatment response. Haas DW Curr HIV/AIDS Rep; 2006 Jul; 3(2):53-8. PubMed ID: 16608660 [TBL] [Abstract][Full Text] [Related]
14. Novel approaches for the treatment of HIV. Arroyo HT Newsline People AIDS Coalit N Y; 1998 Mar; ():16-7. PubMed ID: 11367450 [TBL] [Abstract][Full Text] [Related]
15. [Valuable combination partner. Great benefit for therapy naive patients]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061 [No Abstract] [Full Text] [Related]
17. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061 [TBL] [Abstract][Full Text] [Related]
18. Efavirenz and retinal toxicity. Lewis A; Mitchell S Eye (Lond); 2002 Jan; 16(1):107. PubMed ID: 11913879 [No Abstract] [Full Text] [Related]
19. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. DiCenzo R; Forrest A; Squires KE; Hammer SM; Fischl MA; Wu H; Cha R; Morse GD; Antimicrob Agents Chemother; 2003 Jun; 47(6):1929-35. PubMed ID: 12760869 [TBL] [Abstract][Full Text] [Related]
20. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]